TelyRx Q1 FY26 net loss widens to US$4.7 million; revenue rises 180% to US$19.4 million

  • Apolo V Acquisition Corp. posted Q1 2026 results at TelyRx with revenue rising 35% sequentially to USD 19.4 million.
  • Net loss widened to USD 4.7 million, swinging from break-even a year earlier.
  • Gross profit climbed to USD 10.7 million; gross margin was 55%.
  • Prescriptions filled increased to 236,000, up from 177,000 in Q4 2025.
  • Vanessa Slowey said results reflect growing demand for convenient, affordable healthcare, citing 69,000 new customers and repeat customers accounting for majority of revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apolo V Acquisition Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605121757NEWSFILECNPR____20260512_297239_1) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.